Skip to content
Peptide research

GHRP-2

Also known as Pralmorelin
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic growth hormone secretagogue (ghrelin-receptor agonist), marketed for anti-aging, body composition, and sleep. Its one solid effect is raising growth hormone, which supports its use as a GH-deficiency diagnostic. The fat-loss and sleep benefits people want stay speculative in humans. Being non-selective, it also raises appetite, cortisol, and prolactin, plus water retention and joint pain. Not an approved US drug, and banned in competitive sport.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Potent growth hormone release

    High

    Human trials show a large GH rise, roughly 13-fold over placebo in one study.

  • Diagnostic tool for GH deficiency

    Medium

    Approved in Japan and validated in human trials as a GH deficiency test.

  • Appetite stimulation and orexigenic effects

    High

    Human studies show increased food intake, roughly 36% in healthy men.

Evidence limits

Evidence Level
Moderate

Human clinical data from ~15 published studies including Phase I PK/PD in children (n=10), diagnostic studies in short-stature children (n=24), comparative endocrine studies in young and elderly adults (n=12), food intake studies in healthy men (n=7), critical illness RCT (n=33), and diagnostic evaluation in hypothalamic-pituitary disorders (n=36). Approved as diagnostic agent in Japan. Never progressed past Phase II for therapeutic indications due to reduced efficacy in GHD patients and complex side effect profile.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active cancer

    High

    Potent GH secretagogue — GH/IGF-1 elevation promotes tumor growth.

  • Diabetic retinopathy

    High

    GH/IGF-1 axis activation can accelerate retinal damage.

  • Diabetes/insulin resistance

    Moderate

    GH elevation can worsen blood sugar control.

  • Obesity with appetite issues

    Moderate

    GHRP-2 strongly stimulates appetite via ghrelin pathway.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Reliably increases hunger and food intake (~36%)

    High
  • Stimulates the HPA axis, raising ACTH and cortisol

    Moderate
  • Stimulates prolactin release

    Low
  • GH/IGF-1 elevation causes water retention (bloating, joint pain)

    Moderate
  • Carpal-tunnel-type symptoms from fluid retention/IGF-1

    Low
  • Flushing from ghrelin receptor activation

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.